
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
In Search of a Sterile Fill
over 17 years ago
New Leadership and More Resources Aim to Modernize FDA Operationsover 17 years ago
Coming Down the Pike: Treating Epilepsyover 17 years ago
Inside USP: Heparin Monographs Further Revisedover 17 years ago
Changes to Vial Labels May Affect Patient Safetyover 17 years ago
A Call for Transparency in Research and Marketingover 17 years ago
Critical Challenges Require Core Valuesover 17 years ago
Detective Work




